LINDSAY O'NEIL: Open Payments
NPI 1508113929 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,504 in 298 payments from 21 companies in 2025. Trend: 2023 $2,182 · 2024 $3,365 · 2025 $4,504
Food & beverage: $4,453Education: $51
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 52 | $826 |
| ABBVIE INC. | 46 | $683 |
| Madrigal Pharmaceuticals | 41 | $616 |
| GENZYME CORPORATION | 17 | $348 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $276 |
| Gilead Sciences, Inc. | 18 | $276 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $246 |
| Phathom Pharmaceuticals, Inc. | 28 | $239 |
| Lilly USA, LLC | 13 | $209 |
| Ardelyx, Inc. | 25 | $200 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, RINVOQ, XIFAXAN, VOQUEZNA, OMVOH, IBSRELA.
Industry payments across NE — which companies pay providers there.
